ReviewFrontiers in immunology2021
MRGPRX2 and Adverse Drug Reactions.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 103 citations in OpenAlex.
- Effect of Intradermal Morphine on Histaminergic and Non-Histaminergic Itch: A Randomised, Single-Blinded, Human Study.Experimental dermatology · 2025Trial
- Under the Drapes: Unmasking the Mechanisms and Clinical Diagnosis of Perioperative Hypersensitivity.Current allergy and asthma reports · 2026Review
- Hypersensitivity Reactions to Biologics: Advances in Diagnosis and Management.Current allergy and asthma reports · 2026Review
- Article
- Allergic reaction to nalbuphine administration in a pre-adolescent patient: a case report and literature review.BMC anesthesiology · 2026Review
- Mast Cells and Substance P: Neuroinflammatory Loops at the Molecular and Translational Clinical Levels.Biomolecules · 2026Review
- Mas-Related G-Protein-Coupled Receptors: Emerging Roles in Neuropathic Pain.Biomolecules · 2026Review
- Intravenous iron reactions: Insights from an allergy and immunology perspective.The journal of allergy and clinical immunology. Global · 2025Article
- Anaphylaxis to dextromethorphan with positive skin testing: a case report.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2025Article
- Role of Mast Cells in Human Health and Disease: Controversies and Novel Therapies.International journal of molecular sciences · 2025Review
- Recent Insights into the Epidemiology and Management of AnaphylaxisBalkan medical journal · 2025Review
- IgE and non-IgE-mediated pathways in anaphylaxis.Seminars in immunopathology · 2025Review
- Butyrate Selectively Targets Super-Enhancers and Transcriptional Networks Associated with Human Mast Cell Function.European journal of immunology · 2025Article
- Neurogenic Inflammation in Allergic Contact Dermatitis.Biomedicines · 2025Review
- Mast Cells at the Crossroads of Hypersensitivity Reactions and Neurogenic Inflammation.International journal of molecular sciences · 2025Review
- Drug allergy.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2025Review
- Substance Use Disorder as Risk Factor for Intubation in Angioedema: A Nationwide Cohort Study.The Laryngoscope · 2025Article
- The prevalence of genetic variants of the Mas-related G-protein-coupled receptor X2 in patients does not explain perioperative hypersensitivity reactions to neuromuscular blocking agents.Frontiers in pharmacology · 2025Article
- Multiple Abnormal Cutaneous Findings in a Patient With Hypomelanosis of Ito Undergoing General Anesthesia.Anesthesia progress · 2024Article
- Mast Cells in Allergic and Non-Allergic Upper Airways Diseases: Sentinel in the Watchtower.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many adverse reactions to therapeutic drugs appear to be allergic in nature, and are thought to be triggered by patient-specific Immunoglobulin E (IgE) antibodies that recognize the drug molecules and form complexes with them that activate mast cells. However, in recent years another mechanism has been proposed, in which some drugs closely associated with allergic-type events can bypass the antibody-mediated pathway and trigger mast cell degranulation directly by activating a mast cell-specific receptor called Mas-related G protein-coupled receptor X2 (MRGPRX2). This would result in symptoms similar to IgE-mediated events, but would not require immune priming. This review will cover the frequency, severity, and dose-responsiveness of allergic-type events for several drugs shown to have MRGPRX2 agonist activity. Surprisingly, the analysis shows that mild-to-moderate events are far more common than currently appreciated. A comparison with plasma drug levels suggests that MRGPRX2 mediates many of these mild-to-moderate events. For some of these drugs, then, MRGPRX2 activation may be considered a regular and predictable feature after administration of high doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.